Tag Archive for: Oxford Biomedica

©NicoElNino - stock.adobe.com

Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.

© Oxford Biomedica

British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bio’s lead product, DSG3-CAART.

Picture: Rentschler

Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.

Picture: Rentschler

Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.